Hidden payer site-of-care restrictions delay specialty infusions, driving administrative burden and patient harm—and show why transparent criteria and better coordination matter.
I once had a patient called Sarah who had been stable on a high-cost specialty infusion for 8 months. Her prescriber had chosen a hospital outpatient infusion center for good reasons: Sarah had multiple comorbidities, was on a complex medication regimen, and had experienced infusion reactions in the past. The hospital setting allowed for close monitoring. She was doing well.
Then everything stopped. Sarah's payer issued a new policy: high-cost infusions would no longer be covered in hospital outpatient settings. They had to transition to lower-cost home or ambulatory infusion suite alternatives. The medication itself was still approved. Sarah's clinical need hadn't changed. But the payer's benefit design had.
Sarah’s prescriber documented why hospital-based infusion was still clinically necessary. The infusion center submitted additional clinical justification. The specialty pharmacy called the payer repeatedly asking what documentation would satisfy the requirement.
Three weeks later, Sarah still hadn't received her medication. For those 3 weeks, Sarah waited. Her disease progressed slightly during that gap. Her anxiety about the delay increased. Her prescriber was frustrated. The infusion center staff was spending hours on authorization calls that should have taken minutes. The specialty pharmacy was caught in the middle, unable to dispense because the payer wouldn't authorize hospital-based infusion.
This scenario isn't unique. It plays out hundreds of times each day across American health care.2 And it reveals a fundamental problem with how pharmacy benefit managers (PBMs) and payers manage costs: they achieve savings not through transparent, upfront benefit design but through authorization delays, documentation gauntlets, and multi-stakeholder coordination chaos that hides the real cost of "cost containment."1
Here's how it typically works: A patient's physician prescribes an infusion therapy to be administered in a hospital outpatient infusion center. The medication meets medical necessity criteria. The patient may have complex comorbidities, may be newly diagnosed, or, like Sarah, may be stable on therapy but genuinely safer in a monitored setting. The clinical case for hospital-based infusion is documented.
But the payer's benefit design has a different idea. The PBM or payer policy says the drug can be covered, but only if it's administered in a lower-cost site of care. That lower-cost site might be home infusion, an ambulatory infusion suite operated by a different provider, or a mail-order specialty pharmacy network. The message is implicit: hospital-based infusion is more expensive, so therapy will not be covered there unless clinicians prove why they cannot use the preferred, cheaper option.
On its surface, this sounds reasonable. Cost containment is legitimate. But the execution creates a cascade of problems.
What should be a simple authorization becomes a multi-stakeholder coordination nightmare, and the patient's treatment is delayed.
Here's where it gets worse: even when the clinical case for hospital-based infusion is strong, the authorization can still pend or be denied until the provider submits additional documentation explaining why the hospital setting is required.
I've seen this repeatedly: A patient with multiple comorbidities, on complex medication regimens, with a history of infusion reactions who is genuinely safer in a monitored hospital setting still faces a payer request for "additional clinical justification" for hospital-based infusion. Sarah was exactly this patient.
A patient transitioning from inpatient to outpatient care, discharged from the hospital on infusion therapy, who is clinically appropriate for hospital follow-up infusion during that transition, still encounters a payer push to transition immediately to home infusion, despite the clinical rationale for continuity of care.
A new patient starting a high-risk therapy, whose prescriber specifically chose hospital-based infusion for closer monitoring, still faces a payer denial pending documentation that home infusion "isn't appropriate."
In each case, the payer's cost-containment logic is the same: "We prefer lower-cost sites of care, so prove to us why you can't use them." The burden of proof falls on the provider, the infusion center, the specialty pharmacy, and ultimately, the patient. And while they're proving their case, the patient's therapy is delayed.
This is what doesn't get discussed in payer cost-containment strategies: the operational cost of these delays.6
From the provider's perspective, imagine Sarah's prescriber's office spent roughly 4 to 5 hours on prior authorization calls, documentation requests, and follow-up communications. Some practices have entire teams dedicated to payer authorization. Multiply that across hundreds of patients per year, per payer, and you're looking at tens of thousands of hours annually. At a staff cost of $75 per hour, a hospital system managing 200 specialty infusion patients across 3 major payers—with each patient requiring an average of 2 to 3 site-of-care authorizations per year—is spending $34,000 or more annually just coordinating these approvals. That's administrative overhead that doesn't improve patient care.
From the infusion provider's perspective, consider scheduling delays, staff coordination across multiple payers with different rules, and the operational friction of managing patients across preferred and non-preferred networks. Each payer has different site-of-care policies, different documentation requirements, and different approval timeframes. Sarah's infusion center had to manage her case across the hospital's internal scheduling, the specialty pharmacy's inventory, and the payer's authorization timeline—3 separate systems with no real coordination mechanism.
From the specialty pharmacy perspective, consider holding medication while authorization hangs in limbo, managing communications across multiple parties, and the clinical risk of delayed therapy initiation. During Sarah's 3-week wait, the specialty pharmacy was holding her medication, managing calls from 3 different stakeholders, and unable to dispense because the payer hadn't authorized.
From the patient's perspective, consider treatment delays, uncertainty, potential clinical deterioration if the delay extends long enough, and the stress of navigating a system that approved their medication but won't deliver it on schedule.5 Sarah wasn't just waiting. She was worrying. She was wondering if her disease was progressing during those 3 weeks. She was frustrated that a medication she'd been stable on was suddenly uncertain.
The payer saves money by pushing patients toward lower-cost infusion sites. But the system as a whole—providers, pharmacies, infusion centers, and patients—absorbs an enormous operational and clinical cost.3
The deeper problem is coordination. No single entity has visibility into the entire authorization pathway. The prescriber doesn't know what the payer requires until they submit. The specialty pharmacy doesn't know the prescriber's clinical reasoning until they call. The infusion center doesn't know what documentation the payer wants until the authorization pends. The patient knows even less.
What should be a coordinated handoff between 4 stakeholders—prescriber, specialty pharmacy, infusion provider, and payer—becomes 4 separate conversations, often without full information flowing in either direction. And the patient, waiting for their critical medication, is caught in the middle.
I've spent years in this role: calling payers to clarify benefit design, identifying documentation gaps, communicating with provider offices, and helping navigate the appropriate coverage pathway. The goal is always the same: minimize treatment delays and get the patient access to approved therapy.
But here's what I've learned: a massive amount of this coordination could be prevented with better benefit transparency and communication upfront.
If prescribers knew about site-of-care restrictions before they prescribed, they could document their clinical rationale in the initial prescription, not scramble to provide it days later when the payer challenges the authorization. Sarah's prescriber would have known upfront that the payer requires specific documentation for hospital-based infusion.
If payers published clear criteria for what triggers a site-of-care restriction and what documentation satisfies those criteria, providers could supply it proactively.4 Instead, providers discover the restriction after submission and have to guess what will satisfy the payer. If specialty pharmacies and infusion centers had direct visibility into payer policies, they could communicate needs upfront rather than discovering them after the patient is in the queue. Instead, we have a system where cost containment is achieved through benefit design opacity, and coordination friction is the cost.
I'm not arguing that payers shouldn't manage costs. They should. High-cost infusion therapies are legitimately expensive, and payer cost-containment is part of a functioning health care system. But cost containment should not come at the expense of care coordination or treatment delays for patients whose clinical need is established.
There are models that work better, such as the following:
Transparent benefit design: Clear, published criteria for when hospital-based infusion is covered and what documentation satisfies those criteria. Providers know the rules upfront.
Pre-coordination workflows: A mechanism for prescribers, specialty pharmacies, and infusion providers to coordinate with the payer before the patient is in urgent need of therapy. A single upfront conversation instead of 3 weeks of back-and-forth.
Clinical criteria that account for real-world complexity: Recognizing that some patients genuinely require hospital-based infusion—those with complex comorbidities, unstable conditions, high infusion reaction risk, or those transitioning from inpatient to outpatient care. Like Sarah.
Site-of-care flexibility: Allowing clinical judgment to drive site-of-care decisions, with cost-savings achieved through preferred networks rather than through authorization delays.
For those of us navigating this system daily, when you see a site-of-care mismatch between prescriber intent and payer policy, call the prescriber's office before authorization is submitted. Say, “Your patient is prescribed hospital-based infusion, but I know this payer requires specific documentation. Can you add that to the chart now?" You just saved weeks of back-and-forth. This single conversation is often the difference between a 3-day authorization and a 3-week delay.
Know the payer landscape. Understand which payers have site-of-care restrictions, what documentation they require, and what their timeframes typically are. Call the specialty pharmacy and infusion provider before the patient is scheduled. Clarify what the payer requires. Identify documentation gaps before the authorization hangs in limbo. Build relationships with payer medical directors so you can escalate appropriately when delays become unreasonable.
When authorization delays are genuinely harming the patient, escalate. Request expedited review. Document the clinical impact of delay. Make the case that cost savings are not worth treatment delays for patients with established clinical needs. For Sarah, we eventually escalated to the payer's medical director, who approved the hospital-based infusion once she understood the clinical complexity. The delay wasn't necessary. It was a system failure.
For patients prescribed a high-cost infusion therapy, help them understand their benefit design. Encourage them to ask their provider and specialty pharmacy about site-of-care restrictions before scheduling the infusion. Know what their payer covers and what they don't. Don't assume the provider knows the rules—many don't until after they prescribe.
Don't assume approval means immediate access. Insurance approval of the medication does not automatically mean immediate infusion. Site-of-care restrictions and preferred networks can create delays even after the drug is approved. Encourage patients to ask their provider to clarify the expected timeline for the first infusion. If they're not sure, that's a red flag that coordination hasn't happened yet.
Ask about the timeline. If the authorization is pending, ask the provider's staff or specialty pharmacy how long it typically takes. Days? Weeks? What documentation might be missing? If it's been more than a week and nobody can explain why, escalate.
Help the patient know who to call. If they’ve been waiting longer than expected, tell them to call the provider's office, the specialty pharmacy, and the infusion center. Someone is managing the payer authorization on their behalf—make sure they're moving it forward.
Mohammed Chammout, PharmD, is a community pharmacist with more than 5 years of experience navigating pharmacy benefit design, specialty drug access, and payer authorization pathways. His practice focus includes high-cost specialty therapies, infusion coordination, and helping patients and providers navigate payer policies to minimize treatment delays. He writes about practical pharmacology and health care system challenges for health care professionals and patients.
Site-of-care restrictions are a legitimate cost-containment tool. But the way they're currently implemented with opacity, multi-stakeholder coordination gaps, and treatment delays creates unnecessary friction in a system that's already complex.
Sarah's 3-week delay wasn't because the payer rejected her medication. It was because the system lacked basic coordination. A single conversation upfront between her prescriber and the payer clarifying what documentation was needed could have prevented all of it.
Patients with documented clinical need for hospital-based infusion shouldn't wait weeks for authorization while payers extract additional documentation. Prescribers shouldn't discover site-of-care restrictions after the prescription is already submitted. Specialty pharmacies and infusion centers shouldn't be left guessing about payer criteria.
Better benefit design, transparency, and coordination workflows would maintain cost control while eliminating unnecessary delays. The question is whether payers and benefit designers are willing to prioritize care coordination as seriously as they prioritize cost containment.
From the pharmacy counter, where I see patients like Sarah waiting for treatment that's already approved, the answer is clear: it's time they did.
